Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReCode Therapeutics CNS program
- Development stage
- Preclinical
- Lead developer
- ReCode Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intrathecal
01
Overview
ReCode Therapeutics is developing a preclinical-stage program targeting central nervous system (CNS) diseases using its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform. Announced in 2022 as part of a Series B financing expansion, this program aims to deliver genetic medicines—including mRNA, siRNA, or gene correction modalities—directly to specific cells in the brain, bypassing the liver. While the specific molecular targets and indications remain undisclosed, the program leverages SORT LNPs to enable precise delivery beyond the respiratory system, which is the company's primary focus.
Beyond the preview
Go deeper on ReCode Therapeutics CNS program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReCode Therapeutics CNS program.